Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velaglucerase alfa - Takeda

Drug Profile

Velaglucerase alfa - Takeda

Alternative Names: GA-GCB; GCB; Gene-activated glucocerebrosidase; Glucocerebrosidase - Takeda; Glucosylceramidase - Takeda; Vpriv

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire; Takeda
  • Class Glucosidases; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I
  • No development reported Gaucher's disease type III

Most Recent Events

  • 19 Sep 2019 Shire plans a clinical trial for Gaucher's Disease in Canada (NCT04094181)
  • 01 Aug 2019 No development reported - Phase-I/II for Gaucher's disease type III (In adolescents, In children) in Tunisia, Egypt, India (IV) (Takeda pipeline, August 2019)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top